insights_auto
Outlook: 55.6% bullish·0.0% bearish
Go to analysischevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
31,38 USD
0,00%
(0,00) 1D
9-ноя., 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Mkt. cap
1,87 млд
Avg. vol.
1,29 млн
Volume
9,00
52-wk high
46,00 USD
52-wk low
22,24 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Mkt. cap
1,87 млд
Avg. vol.
1,29 млн
Volume
9,00
52-wk high
46,00 USD
52-wk low
22,24 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
Quantisnow
·
10 мүнөт мурун
ENHA reverse split: 1-for-10 effective Oct 29, 2026
Quartz
·
31 мүнөт мурун
S&P 500 futures flat ahead of October CPI inflation report
24/7 Wall St.
·
50 мүнөт мурун
3 Highest-Yielding Nasdaq Stocks That Are a Top Buy for December
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc